Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Valeant Pharmaceuticals International Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Our first question comes from Gregg Gilbert with Bank of America and Merrill Lynch. Your line is open. Gregg Gilbert - Bank of America-Merrill Lynch Thank you. Good morning guys. Peter, so that we can focus on your operating metrics more clearly, can you walk...
- Earnings calls 2009-02-24
Additional Resources
- Valeant Pharmaceuticals to Initiate Retigabine Phase 3 Clinical Trials; Retigabine Represents the First in a New Class of Epilepsy Treatments; First of Two Phase 3 Studies to Initiate Enrollment in Third Quarter of 2005
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it intends to initiate enrollment in the third quarter of 2005, for a Phase 3 trial for retigabine, which is being developed as an adjunctive treatment for partial-onset seizures in patients with epilepsy. The trial is one of two...
- Research articles 2005-07-26
- Valeant Pharmaceuticals Appoints PAREXEL to Assist with Retigabine Regulatory Applications
- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has appointed PAREXEL International Corp. to develop, coordinate and prepare the New Drug Application NDA and the European Marketing Authorization Application MAA for Valeant's investigational compound retigabine. Retigabine is a novel neuronal potassium-channel opener that is being studied...
- Research articles 2007-05-29
- Valeant Pharmaceuticals to Initiate Study of Retigabine for Pain Associated with Post-Herpetic Neuralgia
- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it will initiate a clinical trial with retigabine in the treatment of pain associated with post-herpetic neuralgia PHN. Valeant filed an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA and following FDA review, the...
- Research articles 2007-05-31
- Valeant?s Pain Drug Disappoints
- Zacks.com submits: Yesterday, Valeant Pharmaceuticals International VRX announced the failure of its drug candidate, retigabine, in a mid-stage study. The trial evaluated retigabine for pain associated with postherpetic neuralgia (PHN), which is common in shingles. The company’s shares closed down 8.5% at $ 24.85. Retigabine was tested in...
- External links 2009-08-25
- Valeant Pharmaceuticals to Acquire Xcel Pharmaceuticals; Acquisition Expands Valeant's Neurology Franchise in North America; Adds Retigabine to Pipeline
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire Xcel Pharmaceuticals, a privately held specialty pharmaceutical company focused on neurology products in the United States. The transaction significantly expands Valeant's business in North America and enhances the company's neurology franchise...
- Research articles 2005-02-02
- Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
- - RESTORE2 Trial Enrolls 539 Patients Across 69 Investigational Sites; NDA Filing on Track for Mid-2008 -
- Research articles 2007-11-27
- Valeant Pharmaceuticals International Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions Our first question comes from the line of Gregg Gilbert of Banc of America Merrill Lynch. Your line is open. Gregg Gilbert - BAS-ML Thanks, good morning. First of all Peter, what's the biggest change in guidance? Is it lower SG&A and R&D...
- Earnings calls 2009-05-05
- << Previous
- page 1 of 1
- Next >>
Presented by American Express